---
title: "益方生物科技(上海)股份有限公司 (688382.SH)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/688382.SH.md"
symbol: "688382.SH"
name: "益方生物科技(上海)股份有限公司"
industry: "生物技術"
---

# 益方生物科技(上海)股份有限公司 (688382.SH)

| Item | Detail |
|------|--------|
| Industry | 生物技術 |
| Location | 滬深市場 |
| Website | [www.inventisbio.com](https://www.inventisbio.com) |

## Company Profile

公司以解決尚未滿足的臨床需求為理念，致力于研制出具有自主知識產權、中國創造並面向全球的創新藥物，持之以恆地為患者提供更加安全、有效、可負擔的治療方案。公司是一家立足中國具有全球視野的創新型藥物研發企業，聚焦于腫瘤、代謝及自身免疫性疾病等重大疾病領域。公司主要產品包括甲磺酸貝福替尼 (BPI-D0316)、格索雷塞 D-1553、D-0502、D-0120、D-2570、YF087、YF055、蛋白抑制劑等。

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-17T04:30:07.000Z

**Overall: C (0.42)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 31 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 132.90% |  |
| Net Profit YoY | 66.59% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 7.64 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 12.73B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 180.53M |  |


**Multi Score**: C

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -6.84% | D |
| Profit Margin | -64.41% | E |
| Gross Margin | 86.50% | A |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 132.90% | A |
| Net Profit YoY | 66.59% | A |
| Total Assets YoY | -6.71% | D |
| Net Assets YoY | -4.01% | D |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -155.25% | D |
| OCF YoY | 132.90% | A |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.10 | E |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 5.61% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 益方生物科技(上海)股份有限公司",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-6.84%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-64.41%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "86.50%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "132.90%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "66.59%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-6.71%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-4.01%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-155.25%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "132.90%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.10",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "5.61%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 百濟神州-U (SH.688235) | C | A | B | C | A | B |
| 02 | 甘李藥業 (SH.603087) | B | B | D | A | B | B |
| 03 | 三生國健 (SH.688336) | A | B | D | B | C | B |
| 04 | 百奧賽圖 (SH.688796) | A | A | C | D | B | B |
| 05 | 天壇生物 (SH.600161) | B | B | C | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -109.47 | 73/83 | - | - | - |
| PB | 7.64 | 63/83 | 11.41 | 9.72 | 7.00 |
| PS (TTM) | 70.51 | 81/83 | 136.56 | 104.99 | 84.64 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-01-29T16:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 3 | 75% |
| Overweight | 1 | 25% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 22.01 |
| Highest Target | 49.25 |
| Lowest Target | 49.25 |

## References

- [Company Overview](https://longbridge.com/en/quote/688382.SH/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/688382.SH/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/688382.SH/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.